Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
$0.97
-1.5%
$0.92
$0.43
$1.77
$483.65M1.561.36 million shs932,183 shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$13.16
-7.3%
$14.57
$10.57
$33.33
$2.07B1.231.93 million shs1.64 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.74
+5.4%
$2.55
$1.83
$7.48
$2.46B0.38.57 million shs26.97 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$36.21
-2.4%
$18.38
$8.24
$39.20
$2.46B-0.292.59 million shs1.68 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
-1.45%-18.43%-1.21%+105.01%-41.52%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-7.26%-15.10%-10.48%-6.07%-57.23%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+5.38%+13.69%+7.45%-3.52%-23.46%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-2.40%+0.78%+149.38%+162.77%+207.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
$0.97
-1.5%
$0.92
$0.43
$1.77
$483.65M1.561.36 million shs932,183 shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$13.16
-7.3%
$14.57
$10.57
$33.33
$2.07B1.231.93 million shs1.64 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.74
+5.4%
$2.55
$1.83
$7.48
$2.46B0.38.57 million shs26.97 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$36.21
-2.4%
$18.38
$8.24
$39.20
$2.46B-0.292.59 million shs1.68 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
-1.45%-18.43%-1.21%+105.01%-41.52%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-7.26%-15.10%-10.48%-6.07%-57.23%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+5.38%+13.69%+7.45%-3.52%-23.46%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-2.40%+0.78%+149.38%+162.77%+207.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
3.00
BuyN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.12
Buy$33.50154.56% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$10.75292.34% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.83
Moderate Buy$43.5020.13% Upside

Current Analyst Ratings Breakdown

Latest CRLBF, MLYS, IBRX, and DNLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$26.00 ➝ $50.00
9/10/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/9/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $52.00
9/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
9/8/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$42.00
9/3/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$15.00 ➝ $26.00
8/28/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $43.00
8/26/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/18/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$33.00 ➝ $30.00
8/14/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
$724.34M0.66N/AN/A$0.79 per share1.23
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M5.82N/AN/A$8.53 per share1.54
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M175.71N/AN/A($0.57) per share-4.81
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
-$74.44M-$0.13N/AN/AN/A-6.67%-11.77%-3.22%11/14/2025 (Estimated)
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)

Latest CRLBF, MLYS, IBRX, and DNLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$0.78-$0.66+$0.12-$0.66N/AN/A
8/11/2025Q2 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A
8/7/2025Q2 2025
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
-$0.04-$0.05-$0.01-$0.05$162.00 million$163.62 million
8/5/2025Q2 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
1.33
3.10
2.22
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.01
10.27
10.27
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.11
3.98
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
15.12
15.12

Institutional Ownership

CompanyInstitutional Ownership
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
0.05%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
N/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cresco Labs Inc. stock logo
CRLBF
Cresco Labs
2,900491.02 millionN/ANot Optionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430146.21 million127.94 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590945.26 million219.39 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2866.30 million44.26 millionOptionable

Recent News About These Companies

Mineralys Therapeutics falls -4.9%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cresco Labs stock logo

Cresco Labs OTCMKTS:CRLBF

$0.97 -0.01 (-1.45%)
As of 09/15/2025 03:59 PM Eastern

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$13.16 -1.03 (-7.26%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$13.30 +0.14 (+1.03%)
As of 09/15/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.74 +0.14 (+5.38%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$2.78 +0.04 (+1.46%)
As of 09/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$36.21 -0.89 (-2.40%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$36.22 +0.01 (+0.01%)
As of 09/15/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.